Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Emactuzumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Emactuzumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Emactuzumab. |
| Estrone | Estrone may increase the thrombogenic activities of Emactuzumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Emactuzumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Emactuzumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Emactuzumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Emactuzumab. |
| Estriol | Estriol may increase the thrombogenic activities of Emactuzumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Emactuzumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Emactuzumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Emactuzumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Emactuzumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Emactuzumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Emactuzumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Emactuzumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Emactuzumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Emactuzumab. |
| Equol | Equol may increase the thrombogenic activities of Emactuzumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Emactuzumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Emactuzumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Emactuzumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Emactuzumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Emactuzumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Emactuzumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Emactuzumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Emactuzumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Emactuzumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Emactuzumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Emactuzumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Emactuzumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Emactuzumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Emactuzumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Emactuzumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Emactuzumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emactuzumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Emactuzumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Emactuzumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Emactuzumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Emactuzumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Emactuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Emactuzumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emactuzumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emactuzumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Emactuzumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emactuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emactuzumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Emactuzumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emactuzumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Emactuzumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Emactuzumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Emactuzumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emactuzumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Emactuzumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Emactuzumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Emactuzumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Emactuzumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Emactuzumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Emactuzumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Emactuzumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Emactuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Emactuzumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Emactuzumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Emactuzumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Emactuzumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Emactuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Emactuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Emactuzumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Emactuzumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Emactuzumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Emactuzumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Emactuzumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Emactuzumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Emactuzumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Emactuzumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Emactuzumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Emactuzumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Emactuzumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Emactuzumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Emactuzumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Emactuzumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Emactuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Emactuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Emactuzumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Emactuzumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Emactuzumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Emactuzumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Emactuzumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Emactuzumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Emactuzumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Emactuzumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Emactuzumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Emactuzumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Emactuzumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Emactuzumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Emactuzumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Emactuzumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Emactuzumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Emactuzumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Emactuzumab. |